BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021;13:906. [PMID: 34207408 DOI: 10.3390/pharmaceutics13060906] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Takács MP. Measuring the half-life of (215)Po by low-level liquid scintillation counting. Appl Radiat Isot 2023;193:110674. [PMID: 36682309 DOI: 10.1016/j.apradiso.2023.110674] [Reference Citation Analysis]
2 Karlsson J, Schatz CA, Wengner AM, Hammer S, Scholz A, Cuthbertson A, Wagner V, Hennekes H, Jardine V, Hagemann UB. Targeted thorium-227 conjugates as treatment options in oncology. Front Med (Lausanne) 2022;9:1071086. [PMID: 36726355 DOI: 10.3389/fmed.2022.1071086] [Reference Citation Analysis]
3 Chatterjee S, Czerwinski KR, Fitzgerald HA, Lakes AL, Liao Z, Ludwig RC, Mcbride KM, Vlasenko VP. Delivery of radiopharmaceuticals and theranostic agents: targeted alpha therapy. Novel Platforms for Drug Delivery Applications 2023. [DOI: 10.1016/b978-0-323-91376-8.00012-4] [Reference Citation Analysis]
4 Brühlmann SA, Kreller M, Pietzsch H, Kopka K, Mamat C, Walther M, Reissig F. Efficient Production of the PET Radionuclide 133La for Theranostic Purposes in Targeted Alpha Therapy Using the 134Ba(p,2n)133La Reaction. Pharmaceuticals 2022;15:1167. [DOI: 10.3390/ph15101167] [Reference Citation Analysis]
5 Wharton L, Jaraquemada-peláez MDG, Zhang C, Zeisler J, Rodríguez-rodríguez C, Osooly M, Radchenko V, Yang H, Lin K, Bénard F, Schaffer P, Orvig C. H 4 picoopa─Robust Chelate for 225 Ac/ 111 In Theranostics. Bioconjugate Chem . [DOI: 10.1021/acs.bioconjchem.2c00364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Liu W, Ma H, Liang R, Chen X, Li H, Lan T, Yang J, Liao J, Qin Z, Yang Y, Liu N, Li F. Targeted Alpha Therapy of Glioma Using 211At-Labeled Heterodimeric Peptide Targeting Both VEGFR and Integrins. Mol Pharm 2022. [PMID: 35993583 DOI: 10.1021/acs.molpharmaceut.2c00349] [Reference Citation Analysis]
7 Hu A, Simms ME, Kertesz V, Wilson JJ, Thiele NA. Chelating Rare-Earth Metals (Ln3+) and 225Ac3+ with the Dual-Size-Selective Macrocyclic Ligand Py2-Macrodipa. Inorg Chem 2022. [PMID: 35914099 DOI: 10.1021/acs.inorgchem.2c01998] [Reference Citation Analysis]
8 Tashima H, Yamaya T. Compton imaging for medical applications. Radiol Phys Technol 2022. [PMID: 35867197 DOI: 10.1007/s12194-022-00666-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Brown MA. Separation of radium and actinium using zirconia. Applied Radiation and Isotopes 2022;185:110238. [DOI: 10.1016/j.apradiso.2022.110238] [Reference Citation Analysis]
10 Miederer M. Alpha emitting nuclides in nuclear medicine theranostics. Nuklearmedizin 2022;61:273-9. [PMID: 34624903 DOI: 10.1055/a-1650-9995] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Daly SR, Bellott BJ, McAlister DR, Horwitz EP, Girolami GS. Pr(H3BNMe2BH3)3 and Pr(thd)3 as Volatile Carriers for Actinium-225. Deposition of Actinium-Doped Praseodymium Boride Thin Films for Potential Use in Brachytherapy. Inorg Chem 2022. [PMID: 35510902 DOI: 10.1021/acs.inorgchem.2c00442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert Opin Biol Ther 2022;:1-7. [PMID: 35350938 DOI: 10.1080/14712598.2022.2060735] [Reference Citation Analysis]
13 Wharton L, Zhang C, Yang H, Zeisler J, Radchenko V, Rodríguez-Rodríguez C, Osooly M, Patrick BO, Lin KS, Bénard F, Schaffer P, Orvig C. [213Bi]Bi3+/[111In]In3+-neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma─Structural, Radiochemical, and Biological Evaluation. Bioconjug Chem 2022. [PMID: 35239331 DOI: 10.1021/acs.bioconjchem.2c00038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Li F, Yang Y, Liao J, Liu N. Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Al-adilah H, Feiters MC, Carpenter LJ, Kumari P, Carrano CJ, Al-bader D, Küpper FC. Halogens in Seaweeds: Biological and Environmental Significance. Phycology 2022;2:132-171. [DOI: 10.3390/phycology2010009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Del Olmo-García MI, Prado-Wohlwend S, Bello P, Segura A, Merino-Torres JF. Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers (Basel) 2022;14:584. [PMID: 35158852 DOI: 10.3390/cancers14030584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Wagstaff P, Gabiña PM, Mínguez R, Roeske JC. Alpha particle microdosimetry calculations using a shallow neural network. Phys Med Biol 2022;67:025008. [DOI: 10.1088/1361-6560/ac499c] [Reference Citation Analysis]
18 Kafle A, Armentrout PB. Experimental and computational investigation of the bond energy of thorium dicarbonyl cation and theoretical elucidation of its isomerization mechanism to the thermodynamically most stable isomer, thorium oxide ketenylidene cation, OTh+CCO. Phys Chem Chem Phys 2022;24:842-53. [PMID: 34908066 DOI: 10.1039/d1cp04263g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Edelmann MR. Radiolabelling small and biomolecules for tracking and monitoring. RSC Adv 2022;12:32383-32400. [DOI: 10.1039/d2ra06236d] [Reference Citation Analysis]
20 Lugat A, Gaschet J, Chérel M, Allard M, Guérard F, Kraeber-bodéré F, Ansquer C. Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_34] [Reference Citation Analysis]
21 Hu A, Brown V, MacMillan SN, Radchenko V, Yang H, Wharton L, Ramogida CF, Wilson JJ. Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa. Inorg Chem 2021. [PMID: 34965102 DOI: 10.1021/acs.inorgchem.1c03670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Neels OC, Kopka K, Liolios C, Afshar-Oromieh A. Radiolabeled PSMA Inhibitors. Cancers (Basel) 2021;13:6255. [PMID: 34944875 DOI: 10.3390/cancers13246255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhou X, Dong L, Shen L. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules 2021;26:6997. [PMID: 34834087 DOI: 10.3390/molecules26226997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hanaoka H, Ohshima Y, Suzuki H, Sasaki I, Watabe T, Ooe K, Watanabe S, Ishioka NS. Enhancing the Therapeutic Effect of 2-211At-astato-α-methyl-L-phenylalanine with Probenecid Loading. Cancers (Basel) 2021;13:5514. [PMID: 34771676 DOI: 10.3390/cancers13215514] [Reference Citation Analysis]
26 Yoshimoto M, Yoshii Y, Matsumoto H, Shinada M, Takahashi M, Igarashi C, Hihara F, Tachibana T, Doi A, Higashi T, Fujii H, Washiyama K. Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy. Pharmaceutics 2021;13:1706. [PMID: 34683999 DOI: 10.3390/pharmaceutics13101706] [Reference Citation Analysis]